

# Assessing and Improving the Reliability of In Silico Property Predictions by Incorporating Inhouse Data

**Pranas Japertas** 



• Why do in silico models fail?

Outline

- Knowing when *in silico* models fail assessing Model Applicability Domain (Reliability Index)
- Relating RI to accuracy of predictions
- Improving models with in-house data
- Case studies of model improvement with in-house data
- Connecting measurement and prediction



# Why do in silico models fail?




- Irrelevant descriptors?
- Statistical techniques not sophisticated enough?
- Limited diversity of the training set?
- Improper usage of statistical tools?
- Poor data quality of the training set?



Any model, no matter which descriptors or statistical methods were used in its development cannot be better than the data it is based on.


Every empirical model works only in certain chemical space, where the compounds from the training set are located – boundaries of Model Applicability Domain



Pharma Algorithms

New Compound, we are making prediction for





– Compound in the Training Set of the Model

- Model Space (Applicability Domain)

– New Compound, we are making prediction for

- Chemical Space of in-house compounds



The very FIRST question *in silico* model should answer:

• Is a compound in the Model Applicability Domain (Model Space)? Can we trust this prediction?

What is the predicted value for property X is only the second question.




# Assessing Model Applicability Domain. Reliability Index (RI) as a measure of the quality of a prediction



- Similarity Index
- Data-Model Consistency Index
- Reliability Index






Compound we are making prediction for


Compounds in the training set

The most similar compounds in the training set









Similarity Index (SI) is calculated as weighted average pair wise similarity to n most similar compounds in the training set:


$$SI = \sum_{i=1}^{n} a^{i-1} \cdot SI_i / \sum_{i=1}^{n} a^{i-1}$$



- Similarity Index obtains values in the range from 0 (nothing similar exists) to 1 (n completely similar compounds exist), making it easily understandable and usable
- Similarity Index is a simple but efficient criterion identifying compounds that DO NOT belong to Model Applicability Domain
- But having similar compounds does not necessary means that predictions will accurate and reliable

Let's consider the following example with prediction of Acute Toxicity (LD50) values for the doxorubicin...







Rat, Intraperitoneal administration:

Estimated  $LD_{50} = 13 \text{ mg/kg}$ RI = 0.71


Five most similar compounds with experimental values from the library:








Five most similar compounds with experimental values from the library:





Closer look at the experimental values of LD50s for similar compounds in the training set:




LD50 ranges from 0.5 mg/kg to 700 mg/kg!



• Can we have an idea how well model will perform by looking at similar compounds?








Compound we are making prediction for

Compounds in the training set


The most similar compounds in the training set







1.97	1.75
0.92	0.73
2.28	1.69
1.47	1.93
0.80	0.49




The most similar compounds in the training set

RetrievePredictmeasuredvaluesvaluesusing model

Analyse model performance for those compounds


Pharma Algorithms www.ap-algorithms.com

Two compounds, with the same Similarity Index for both. Scatter plots illustrating model performance for similar compounds.



Which prediction shall we trust more? For compound A or B?

Model performance for similar compounds (2)



# Predicted

## Compound A:

Model predictions for similar compounds agree with experimental data

## **Compound B:**

Model doesn't agree with experimental data

Pharma Algorithms

WWW.AP-ALGORITHMS.COM


#### Reasons:

- 1. Model doesn't work
  - 1. Model doesn't work in general
  - 2. Model doesn't work for this particular class of compounds
  - 3. Similarity doesn't work selected compound are not similar
- 2. Data quality is bad
- 3. Both model and data are bad





Considerations from the previous slides were reflected in the developed Model-Data Consistency Index, which is calculated looking at the predicted and measured values for the similar compounds:



Pharma Algorithms

- $\Delta_i$  Difference between estimated and experimental value for the ith nearest neighbor
- $\Delta$  Average difference for the neighbors
- $SI_{i}$  Similarity to the i<sup>th</sup> nearest neighbor
- a, b Scaling parameters

Reliability Index is a product of Similarity and Model-Data Consistency indices:

# $RI = SI \cdot MDCI$


• RI will be low if SI is low (no similar compounds) OR MDCI (model doesn't agree with the experiment for the similar compounds) is low

• RI will be high only if we have similar compounds AND model performs well compared to measured values on those compounds




# Demonstrating relationship between accuracy of the predictions and Reliability Index (Validation)

System: LogP (training set size: 10593 compounds) Results on the validation set:



 $R^2 = 0.9318$ RMSE = 0.503 N = 5296  $R^2 = 0.9579$  RMSE = 0.404 N = 3486(compounds with estimated RI > 0.75) R<sup>2</sup> = 0.9742 RMSE = 0.313 N = 1220 (compounds with estimated RI > 0.85)

### System: $pK_a$ (base) (training set size: 8335 compounds) Results on the validation set:




R<sup>2</sup> = 0.9453 **RMSE** = 0.723 N = 7950 (compounds with estimated RI > 0.5) R<sup>2</sup> = 0.9757 **RMSE = 0.460** N = 5498 (compounds with estimated RI > 0.8)  $R^{2} = 0.9877$  RMSE = 0.302 N = 3010(compounds with estimated RI > 0.9)



# Improving models using in-house data





– Compound in the Training Set of the Model


- Model Space (Applicability Domain)

– New Compound, we are making prediction for

– Chemical Space of in-house compounds




Prediction algorithm behind Trainable Models consists of two parts:



- Linear, additive method
- Learns global trends and what's "similar" for particular property
- It's constant, doesn't change

- Adds non-linearity
- Makes correction to the original prediction from PLS by analysis of local environment
- It's changing, when new data is added – trainable part of the algorithm






Compound we are making prediction for

Compounds in the training set

The most similar compounds in the training set






The most similar compounds in the training set Retrieve Pre measured val values usi

Predict values using model Do <u>local</u> modeling


## **PLS Illustration**





Simple model relating property y and descriptor x

PLS analysis would come up with linear model  $y = 0.5^*x + 0.7$ 



Now we also explore local environment, analyzing how models performs for similar compounds with known

Let's look at the difference between Observed and Predicted values for those compounds:

Pharma Algorithms

W.AP-ALGORITHMS.COM

On average:  $\Delta$ (mean) = -0.78



# Validation Studies of Trainable Models



# Validation case:

Take existing model of aqueous solubility (based on publicly available data).


Add portions of in-house measured data retraining the model.

Check predictivity against validation set of in-house compounds after each addition of experimental data.



System: Aqueous solubility (training set size varies) Results on the validation set:

	Whole test set		Unreliable removed (RI>0,3)		Moderate and high (RI>0,5)		High (Rl>0,7)	
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100	400	0.894	291	0.873	57	0.710		
Built-in + 250	400	0.868	303	0.841	76	0.703		
Built-in + 500	400	0.821	327	0.774	144	0.586	58	0.469
Built-in + 750	400	0.697	365	0.658	256	0.534	118	0.434
Built-in + 913	400	0.624	382	0.616	304	0.530	154	0.433





	Whole to	est set	Unreliable removed (Rl>0,3)		Moderate and high (RI>0,5)			
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270		48			
Built-in + 100	400	0.894	291		57			
Built-in + 250	400	0.868	303		76			
Built-in + 500	400	0.821	327		144			
Built-in + 750	400	0.697	365		256		118	
Built-in + 913	400	0.624	382	0.616	304		154	

MAE ranges						
(0,8 - 0,9]						
(0,7 - 0,8]						
(0,6 - 0,7]						
(0,5 - 0,6]						
(0,4 - 0,5]						



	Whole to	est set		Unreliable removed (RI>0,3)		Moderate and high (RI>0,5)			
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	
Built-in	400		270	0.841	48				
Built-in + 100	400		291	0.873	57				
Built-in + 250	400		303	0.841	76				
Built-in + 500	400		327	0.774	144				
Built-in + 750	400	0.697	365	0.658	256		118		
Built-in + 913	400	0.624	382	0.616	304		154		

MAE ranges						
(0,8 - 0,9]						
(0,7 - 0,8]						
(0,6 - 0,7]						
(0,5 - 0,6]						
(0,4 - 0,5]						



	Whole to	est set	Unreliable (R	removed RI>0,3)	Moderate and h	nigh (RI>0,5)	High (R	
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400		270		48	0.695		
Built-in + 100	400		291		57	0.710		
Built-in + 250	400				76	0.703		
Built-in + 500	400		327		144	0.586	58	
Built-in + 750	400	0.697			256	0.534	118	
Built-in + 913	400	0.624		0.616	304	0.530	154	

MAE ranges					
(0,8 - 0,9]					
(0,7 - 0,8]					
(0,6 - 0,7]					
(0,5 - 0,6]					
(0,4 - 0,5]					



	Whole t	est set	Unreliable (F	removed RI>0,3)	Moderate and I		High (R	>0,7)
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400		270		48			
Built-in + 100	400		291		57			
Built-in + 250	400				76			
Built-in + 500	400		327		144		58	0.469
Built-in + 750	400	0.697			256		118	0.434
Built-in + 913	400	0.624		0.616	304		154	0.433

iviAE ranges						
(0,8 - 0,9]						
(0,7 - 0,8]						
(0,6 - 0,7]						
(0,5 - 0,6]						
(0,4 - 0,5]						



	Whole to	est set	Unreliable (F	removed RI>0,3)	Moderate and	high (RI>0,5)	High (R	l>0,7)
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100			291		57			
Built-in + 250					76			
Built-in + 500			327		144			
Built-in + 750		0.697			256		118	
Built-in + 913		0.624		0.616	304		154	

WAE ranges						
(0,8 - 0,9]						
(0,7 - 0,8]						
(0,6 - 0,7]						
(0,5 - 0,6]						
(0,4 - 0,5]						



	Whole to	est set	Unreliable (F	removed RI>0,3)	Moderate and	high (RI>0,5)	High (R	l>0,7)
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100	400	0.894	291	0.873	57	0.710		
Built-in + 250	400		303	0.841	76			
Built-in + 500			327		144			
Built-in + 750		0.697			256		118	
Built-in + 913		0.624		0.616	304		154	

MAE ranges					
(0,8 - 0,9]					
(0,7 - 0,8]					
(0,6 - 0,7]					
(0,5 - 0,6]					
(0,4 - 0,5]					



	Whole test set		Unreliable removed (RI>0,3)		Moderate and high (RI>0,5)		High (RI>0,7)	
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100			291		57			
Built-in + 250	400	0.868	303	0.841	76	0.703		
Built-in + 500	400	0.821	327	0.774	144	0.586	58	0.469
Built-in + 750		0.697			256		118	
Built-in + 913		0.624		0.616	304		154	

MAE range	es
(0,8 - 0,9]	
(0,7 - 0,8]	
(0,6 - 0,7]	
(0,5 - 0,6]	
(0,4 - 0,5]	



	Whole test set		Unreliable removed (RI>0,3)		Moderate and high (RI>0,5)		High (RI>0,7)	
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100			291		57			
Built-in + 250					76			
Built-in + 500	400	0.821	327	0.774	144	0.586	58	0.469
Built-in + 750	400	0.697	365	0.658	256		118	0.434
Built-in + 913		0.624		0.616	304		154	

MAE range	es
(0,8 - 0,9]	
(0,7 - 0,8]	
(0,6 - 0,7]	
(0,5 - 0,6]	
(0,4 - 0,5]	



	Whole test set		Unreliable removed (RI>0,3)		Moderate and high (RI>0,5)		High (RI>0,7)	
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100			291		57			
Built-in + 250					76			
Built-in + 500			327		144			
Built-in + 750	400	0.697	365	0.658	256	0.534	118	0.434
Built-in + 913	400	0.624	382	0.616	304		154	0.433

MAE rang	es
(0,8 - 0,9]	
(0,7 - 0,8]	
(0,6 - 0,7]	
(0,5 - 0,6]	
(0,4 - 0,5]	



	Whole te	est set	Unreliable removed (RI>0,3)		Moderate and high (RI>0,5)		High (RI>0,7)	
Size of the training set	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE	No of cmpds	MAE
Built-in	400	0.900	270	0.841	48	0.695		
Built-in + 100			291		57			
Built-in + 250					76			
Built-in + 500			327		144			
Built-in + 750		0.697			256		118	0.434
Built-in + 913	400	0.624	382	0.616	304	0.530	154	0.433

MAE range	es
(0,8 - 0,9]	
(0,7 - 0,8]	
(0,6 - 0,7]	
(0,5 - 0,6]	
(0,4 - 0,5]	




Any model, no matter which descriptors or statistical methods were used in its development cannot be better than the data it is based on.

Every empirical model works only in certain chemical space, where the compounds from the training set are located – boundaries of Model Applicability Domain

Even within Model Applicability Domain model cannot get more accurate than the unexplainable variation in measured values. 1. Measurements from the same laboratory

2. Same protocol from several laboratories

3. Compilation of publicly available data





Better accuracy is achieved because:

- Chemical space is much better represented, model learns structureproperty relationships for new chemical classes
- Several layers of data "noise" are removed as we use much more consistent data model "learns" your methodology, your protocol



## Improving models using in-house data. How many compounds do you need to improve a model?




## Validation case:

Special built LogP model – no beta-lactam antibiotics in the training set!

Add beta-lactam antibiotics with measured LogP one after another to improve the model

Check predictivity against validation set and selected compounds (beta-lactam antibiotics).






Measured LogP = 0.26

Calculated LogP = 1.46Estimated RI = 0.26

Five most similar compounds from the library:





## Prediction results for Phenoxymethylcephalosporin:

	Predicted LogP	RI	Predicted - Observed
Original prediction (no beta lactam antibiotics in the training set)	1.46	0.26	1.2
	1.05	0.53	0.79
	0.62	0.61	0.36
	0.32	0.71	0.06



Applications of the Reliability Index and Traiinable Models – Connecting measurement and prediction



- As it was shown in the previous slides, RI indeed reflects Model Applicability Domain and can be used as indicator of usability of predicted values
- RI can also be used in experiment planning and prioritization of the measurements – most knowledge will be gained measuring compounds for which estimated RI is the lowest.

Pharma Algorithms

#### Scale of Reliability Index:

Low RI values, these compounds should be measured first and if possible added to model We expect that amount of compounds with estimated intermediate Reliability Index will decrease after properties of compounds with low RI will be measured and values added to the model for further improvement High RI values, class of compounds well represented in the training set, model already performs well on those compounds. Measurements would be redundant

# Pharma Algorithms

- Rytis Kubilius
- Andrius Sazonovas
- Remigijus Didžiapetris
- Kiril Lanevskij

# Syngenta

- Eric Clarke
- John Delaney
- Tom Sheldon (Industrial Placement Student, University of Bath)

# PhysChem Forum 5 Organizers



## Thank You for your attention